Atea Pharmaceuticals, Inc. (AVIR)

3.8300 -0.0200 (-0.52%) At close: 04:00PM EDT

Atea Pharmaceuticals, Inc.

225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 75

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jean-Pierre Sommadossi Ph.D.	Founder, Chairman, CEO & President	1.04M	N/A	1956
Ms. Andrea J. Corcoran J.D.	CFO, Executive VP of Legal & Secretary	712.48k	N/A	1962
Mr. Keith Pietropaolo	Senior Vice President of Clinical Sciences	N/A	N/A	N/A
Dr. Jayanthi Wolf Ph.D.	Executive Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Nancy Gail Berry Agrawal Ph.D.	Executive Vice President of Preclinical Development	N/A	N/A	N/A
Ms. Qi Huang	Senior Vice President of Virology	N/A	N/A	N/A
Ms. Kerry Gagnon	VP & Head of Quality	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate Governance

Atea Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 4; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.